ORIGINAL ARTICLE. Wound Healing Trajectories as Predictors of Effectiveness of Therapeutic Agents
|
|
- Alberta Alexander
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Wound Healing Trajectories as Predictors of Effectiveness of Therapeutic Agents Martin C. Robson, MD; Donald P. Hill, PharmD; Matthew E. Woodske, BS; David L. Steed, MD Background: One goal of wound healing research is to discover agents to accelerate healing. Regulatory agencies have suggested stringent criteria to determine efficacy, that of 1% wound closure. Data analysis at a single point such as 1% closure does not provide detailed information about agent effectiveness over the entire span of healing. Hypothesis: Wound healing trajectories can provide such information and can be used to demonstrate utility as alternative end points for wound healing trials. Design: Data from 1 patients in 11 clinical trials of diabetic foot ulcers conducted at 2 centers were evaluated. Wound healing trajectories were constructed for patients whose wounds healed (1% closure) and those whose did not ( 1% closure) over a -week period. The percentage of patients achieving total healing vs time of treatment was plotted and divided into patients receiving a test agent or placebo. Results: The healing trajectories were almost identical for patients achieving complete healing at the 2 centers, as were the trajectories for patients with less than 1% closure. However, the trajectories of patients achieving total healing were significantly different from those not achieving 1% closure. Fifty-two percent of all patients achieved 1% healing by weeks; 61% of patients receiving an experimental agent had total healing compared with 39% of placebo-treated patients. Linear regression suggested that all patients would achieve total healing by 37 weeks. Conclusions: Since wound healing trajectories for diabetic foot ulcers treated at 2 centers so closely mimic one another, trajectories might be useful efficacy end points, and used to compare significant points along a continuum rather than a single static end point. Shifting of the wound healing trajectory from an impaired to a more ideal course may be consideredwhendeterminingefficacyofnewwoundtreatments. Arch Surg. ;135: From the Department of Surgery, University of South Florida, Tampa, and Institute for Tissue Regeneration, Repair, and Rehabilitation, Bay Pines Veterans Affairs Medical Center, Bay Pines, Fla (Drs Robson and Hill); and the Department of Surgery, University of Pittsburgh, Pittsburgh, Pa (Mr Woodske and Dr Steed). SINCE COHEN et al1 first demonstrated that epidermal growth factor directly stimulated the proliferation of epithelial cells in 1965, effects of this recombinant peptide have been sought. Discovery of other growth factors in the 197s helped renew scientific interest in wound healing and encouraged clinical optimism that new treatment modalities for chronic wounds would become available. 2 During these past 2 decades, our understanding of the wound healing response, and the roles that growth factors play in regulating this response, has increased substantially. 3,4 The first use of topically applied growth factors to accelerate wound healing was reported by Brown et al 5 in During the past 1 years, many clinical trials involving the application of exogenous recombinant growth factors have been conducted in an attempt to accelerate healing with mixed success. Recently, the reasons for the indeterminate results have been discussed. 6 The culminative goal of much wound healing research is to discover products and processes that can accelerate wound healing in humans. 7 One problem in the clinical trials to date attempting to discover such therapeutic agents has been trial design, including the methodology and determination of end points. As yet, investigators have not routinely used analytical methods that directly, unambiguously, and unequivocally resolve the bottomline question: using a statistically robust analysis, does the agent under evaluation actually promote wound healing? 8 Different studies have suggested various outcome measures (eg, absolute wound area remaining, 9,1 percentage of initial wound area remaining, 11,12 wound volume remaining, 13 wound perimeter remaining, 11,14 various definitions of wound healing velocities, and the ease of surgical closure of the remaining wound after therapy 19 ). At (REPRINTED) ARCH SURG/ VOL 135, JULY 773 Downloaded From: on 12/4/17 American Medical Association. All rights reserved.
2 PATIENTS AND METHODS Data were obtained on all patients entered into a total of 11 clinical trials of diabetic neuropathic foot ulcers at the 2 centers utilizing multidisciplinary wound care/ research teams. Both centers participated in 3 of the trials, and only the University of Pittsburgh team participated in 6 of the trials and only the University of South Florida/Bay Pines Veterans Affairs Medical Center team participated in 2 of the trials. All patients, regardless of the particular clinical trial, shared 3 basic criteria: (1) all had debridement of all necrotic tissue in and/or surrounding the ulcer prior to study entry and as needed during the trial, (2) all had off-loading of weight to the ulcer area, and (3) all had frequent periodic evaluation by an experienced wound care/research team. Since it was not our intent to focus on the analysis of data from any particular clinical trial, the minimal description of experimental data was sequentially measured diabetic neuropathic foot ulcers in patients treated with various therapeutic wound healing agents, their respective vehicle controls, or standardized care. At all measurement times, the wound perimeters were traced on clear plastic sheets and the wound areas calculated planimetrically. The ulcers were measured weekly for a defined period determined by the parameters of the particular clinical trial, most commonly weeks (1 days). Since 1% healing (total wound closure) was the efficacy standard used in the majority of these clinical trials, wound healing trajectories were constructed for patients who achieved total healing (1% closure) and those who did not ( 1% closure) over a -week period at the 2 centers. In addition, the percentage of patients who achieved total healing was plotted vs time of wound treatment (days) for both centers to determine how patients with diabetic neuropathic foot ulcers receiving at least debridement, off-loading, and frequent monitoring heal their ulcers. Survival analyses were done using the Kaplan- Meier method, with both log-rank and Wilcoxon statistics to test for differences between groups. Percentage healing refers to the diminishment of wound area relative to day zero as follows: [Area (Day ) Area (Day x)/area (Day )] 1. Calculations and graphs were done using JMP software (SAS Institute Inc, Cary, NC) and Sigma Plot software (SPSS Inc, Chicago, Ill). a meeting sponsored by the National Institutes of Health and Food and Drug Administration (FDA) in 1993 titled, Clinical Trial Issues in Topical Wound Healing Biologies, end points for wound healing clinical trials were discussed. Wound closure rates, operative wound closure severity, and quality-of-life end points were suggested, in addition to using the Wound Healing Society s definitions of ideal or acceptable wound healing and complete wound closure. The FDA and a committee of the Wound Healing Society have suggested the most stringent criteria to determine efficacy for a new wound healing agent, that of total (1%) wound closure. 19 Stromberg et al of the FDA have stated, With respect to outcome measurements, complete rather than partial closure of wounds provides the best objective evidence of clinical benefit and therefore is the preferred primary endpoint. 21 They did indicate that in certain indications end points of a clinical trial other than complete (1%) closure may be considered as long as they are validated measurements of patient benefit. Healing of open wounds follows an exponential course, with the rate of change of wound area progressively decreasing as the residual wound area approaches total closure. DeNouy 1 was able to express this phenomenon by developing an equation and designing a curve that represents the theoretical evaluation of the healing of a wound. 1 This curve is similar to the growth curve originally described by Gompertz. 22 Because inclinations of this exponential curve diminish with time, attempts have been made to develop a linear rate of healing. Gilman 14 introduced the concept of using the wound perimeter to neutralize the effect of varying size wounds in calculating the rate of healing. This concept appeared to work satisfactorily for both diabetic 15 and venous stasis ulcers. 16 However, researchers using this manipulation to determine a rate of healing found a different initial healing rate and overall healing rate. 16 This may be due to the various processes of healing necessary to close these wounds as suggested by Snowden. 18 Tallman et al 17 further manipulated the raw data measurement to attempt to get a single healing rate by calculating a rate for each time interval measured and averaging the various intervals. This they called a mean-adjusted healing rate. Hokanson et al 8 proposed an analytical strategy that combined a mathematical model to approximate the actual woundclosuremeasurementsandanendpointanalysissimilar to that used in failure-time studies. This approach leaves the raw data for wound area free of mathematical transformation. That group has shown that this analysis worked when applied to large groups of animal wound healing studies To date, no large studies of human woundshave been evaluated to determine whether such a strategy could be used as an end point to determine efficacy of therapeutic agents in wound healing. Using a dynamic healing trajectory or healing time curve may allow the prediction of healing of an individual wound. To determine a population time to healing, survival study methods as described by Kaplan and Meier 25 can be used. These have been reported for wound healing studies and are useful when there are a significant number of patients who do not complete the entire time course of the study or do not reach the end point under investigation (eg, complete healing). 26,27 Over the past 1 years, 2 multidisciplinary wound research teams, one based at the University of Pittsburgh, Pittsburgh, Pa, and one based at the University of South Florida/Bay Pines Department of Veterans Affairs Medical Center, Bay Pines, Fla, have participated in prospectively randomized clinical trials enrolling 61 patients. These included 1 patients with diabetic neuropathic foot ulcers. The purpose of this report is to demonstrate the usefulness of the wound healing trajectory (plot of percent- (REPRINTED) ARCH SURG/ VOL 135, JULY 774 Downloaded From: on 12/4/17 American Medical Association. All rights reserved.
3 Center 1 Center 2 % of Wounds Healed (Median) Center 1: Healed Center 1: Not Healed Center 2: Healed Center 2: Not Healed % of Patients 1% Healed % of Wounds Healed (Mean) Center 1: Healed Center 1: Not Healed Center 2: Healed Center 2: Not Healed % of Patients 1% Healed Centers 1 and 2 Combined Linear Regression Linear Regression: y = mx + b y =.6x 6.3, r 2 = Figure 1. Curves depicting median (top) and mean (bottom) values for percentage of initial wound healed, by study center. Circles indicate patients who achieved 1% healing; squares, patients who did not achieve complete healing. Because of differences in study designs, data for all 1 patients were not available at all time points. Figure 2. Kaplan-Meier healing curves depicting the percentage of patients achieving 1% wound closure, by study center (top) and both sites combined (bottom). Linear regression curves with derived coefficients are also depicted. Top, Test between centers: log-rank, P=.36; Wilcoxon, P=.27. age of wound closure vs time of wound treatment) in helping to determine efficacy of novel therapeutic agents for wound healing. RESULTS A total of 1 patients with diabetic neuropathic foot ulcers met inclusion/exclusion criteria and were entered into institutional review board approved prospectively randomized clinical trials. Of all the patients entered into these trials at the 2 centers, 73 achieved total healing (1% closure) within weeks. The wound healing trajectories were almost identical for patients achieving complete healing at the 2 centers (Figure 1). This was true whether one evaluated the mean or the median percentage healing vs time of treatment. The trajectories for patients with less than 1% closure over the period of the trials were also remarkably similar. However, the trajectories of the patients achieving total healing were markedly different from those not achieving 1% closure. Survival analysis of patients entering these clinical trials at the 2 centers who achieved total healing each week is shown in Figure 2. This was broken down further for each individual center, and these analyses showed that 52% of all patients at the 2 centers entered into a prospectively randomized clinical trial and receiving the standard care of debridement, off-loading, and regular evaluations healed their wounds 1% by weeks. There was no statistical difference between the 2 centers when the survival analyses were compared (log-rank P=.36; Wilcoxon P=.27). Almost no total healing occurred until 28 days (4 weeks). After 28 days, a linear relationship occurred, with 3% more patients achieving 1% closure per week (12% per month). Although no trials of patients with diabetic foot ulcers conducted at the 2 centers had greater than - week duration, a linear regression analysis was performed to predict when all patients would achieve 1% closure. Based on the linear relationship demonstrated in Figure 2, this would occur at 37 weeks. When the survival analysis was separately determined for patients receiving any experimental agent vs control patients not receiving such treatments, the patients receiving experimental agents had a statistically significant higher incidence of 1% closure (Figure 3). Sixty-one percent of patients receiving one of the experimental agents had total healing (1% closure) at weeks vs 39% of control patients (log-rank P=.2; Wilcoxon P=.4). The linear regressions of the 2 groups suggested that the experimental agents group would all reach 1% wound closure by 32.7 weeks and the controls by 46.1 weeks. COMMENT Improvement in wound healing is a goal that has rapidly gained the interest of clinicians, researchers, and in- (REPRINTED) ARCH SURG/ VOL 135, JULY 775 Downloaded From: on 12/4/17 American Medical Association. All rights reserved.
4 % of Patients 1% Healed Experimental Agent Control Linear Regressions Linear Regressions: y = mx + b Experimental Agent: y =.463x 5.9, r 2 =.98 Control: y =.329x 6.3, r 2 = Figure 3. Kaplan-Meier healing curves depicting the percentage of patients achieving 1% wound closure for patients receiving an experimental agent vs controls. Linear regression curves with derived coefficients are also depicted. dustry. Animal studies have suggested that the various processes of the healing scheme including coagulation, inflammation, matrix synthesis and deposition, angiogenesis, epithelialization, contraction, and remodeling can be accelerated. Measuring this outcome for a particular new therapeutic agent in human clinical trials has been difficult. The FDA, working with a committee of the Wound Healing Society, has suggested that total wound healing (1% closure) is ideal. 21 Trials most commonly have been designed for a defined time period and the percentage of patients achieving 1% closure in the experimental treatment groups compared with those achieving 1% closure in the control (placebo vehicle and/or standard care) groups at the defined time completion point has been the determination of efficacy. The data presented in Figure 2 suggest that all patients with diabetic neuropathic foot ulcers enrolled in clinical trial receiving a level of care of at least debridement of necrotic tissue, weight off-loading, and regular evaluations will achieve 1% wound closure by 9 months. Therefore, if 1% wound closure is the best efficacy end point, a clinical trial of approximately 9 months duration would allow the best determination of this efficacy end point. The practical difficulty and expense of conducting a closely monitored wound healing trial of 9 months duration is immense. The result would be that the patients who were healing on a slower trajectory may drop out before completion of the study. Faster-healing patients would have to remain in a closely monitored follow-up period and could theoretically lower the morale of the slowerhealing patients being followed in the trial. These are some of the reasons for attempting to identify intermediate end points that can serve as valid efficacy end points. Since the wound healing trajectories for diabetic neuropathic foot ulcers treated in clinical trials at 2 totally independent wound care/research centers so closely mimicked one another, it would appear that wound healing trajectories can be validated and may be useful to serve as efficacy end points. This was strengthened by the fact that the trajectories of patients achieving 1% wound closure within weeks were so different from patients not achieving total healing within weeks. Once the wound healing trajectory is plotted, the time required for the percentage healing to reach an arbitrary fraction of 1% closure can be determined. As Hokanson et al 8 have described, the distributions of these fractional closure times and statistical differences in these distributions can then be determined using statistical methods similar to those used for failure-time or survival analyses. For each group the time required to reach an arbitrary percentage of healing, such as 5%, 75%, and 9%, can be determined. These distributions of times to an event (eg, 75% wound closure) can then undergo standard statistical failure-time analysis. 27 These techniques can be used to compare 2 experimental groups or generalized for comparing multiple groups. 8,27 Many of the problems of comparing healing in multiple groups are averted with this method. The wounds are normalized by using a fractional decrease in wound size or percentage closure to be consistent with the analysis of chronic wounds that vary greatly in size. 11 This allows use of raw data and does not require manipulation by introducing the perimeter or a second step of using the perimeter and multiple small time intervals. 17 These latter techniques may not be necessary in diabetic neuropathic foot ulcers that are of limited size, as McGrath and Simon 11 have suggested that the relative rate of closure is remarkably independent of initial wound size. Healing trajectories provide more information about the entire continuum of the wound healing processes. Hokanson et al 8 have illustrated that a t test performed on data from a single point (eg, 1% closure) may not provide accurate guidance about the actual effectiveness of novel therapeutic agents over the entire span of the healing process. All wounds normalized to initial size begin at % healing and all wounds that heal during the defined period of the trial have 1% healing. Statistical comparisons at these extremes may be noninformative and stress the need for statistical techniques that allow dynamic comparisons at biologically meaningful interim values. 8 This point is in agreement with Polansky and van Rijswijk, 26 who state that healing time curves (wound healing trajectories) are a moving picture of healing that provide more detail than the snapshot approach in which only the proportion of patients healed (1% closed) at the end of the study is assessed. 26 Wright et al 28 have suggested that normal and impaired healing exist on a continuum and are a compromise from ideal healing. In attempting to accelerate acute incisional wound healing depicted by a breaking strength or tensile strength vs time curve, they discuss the concept of moving the wound healing process in the direction of the ideal. This essentially shifts the breaking strength vs time curve to the left. Conceptually, the wound healing trajectories used to depict the data of the chronic diabetic neuropathic foot ulcer wounds are similar to the gain in wound strength curves used to depict data from healing acute surgical incisions. Therefore, shifting the trajectory of the patients with less than 1% closure in a defined time period in Figure 1 to the trajectory of patients attaining total closure could be used to determine new therapeutic agent efficacy. If the predictive value of such wound healing trajectories can be determined for the various other types of human chronic wounds, such as pressure ulcers and venous stasis ulcers, possibly shorter (REPRINTED) ARCH SURG/ VOL 135, JULY 776 Downloaded From: on 12/4/17 American Medical Association. All rights reserved.
5 clinical trials can be constructed relying on specific shifts of the wound healing trajectories from impaired healing toward an ideal end point. Corresponding author: Martin C. Robson, MD, Institute for Tissue Regeneration, Repair, and Rehabilitation, Bay Pines VA Medical Center, PO Box 55, Bay Pines, FL Reprints: David L. Steed, MD, Wound Healing/Limb Preservation Clinic, Division of Vascular Surgery/ Department of Surgery, A111 UPMC Presbyterian, Lothrop St, Pittsburgh, PA REFERENCES 1. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. 1965;12: LeGrand EK. Preclinical promise of becaplermin (rhpdgf-bb) in wound healing. Am J Surg. 1998;176(suppl 2A): Schaffer CJ, Nanney LB. Cell biology of wound healing. Int Rev Cytol. 1996;169: Kiritsy CP, Lynch AB, Lynch SE. Role of growth factors in cutaneous wound healing: a review. Crit Rev Oral Biol Med. 1993;4: Brown GL, Nanney LB, Griffen J, et al. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med. 1989;321: Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surg. 1998;176(suppl 2A): Richey KJ, Engrav LH, Pavlin EG, Murray MJ, Gottlieb JR, Walkinshaw D. Topical growth factors and wound contraction in the rat, part I: literature review and definition of the rat model. Ann Plast Surg. 1989;23: Hokanson JA, Hayward PG, Carney DH, Phillips LG, Robson MC. A mathematical model for the analysis of experimental wound healing data. Wounds. 1991; 3: Carrel A, Hartmann A. Cicatrization of wounds, I: the relation between the size of a wound and the rate of its cicatrization. J Exp Med. 1916;24: DuNouy PL. Cicatrization of wounds, II: mathematical expression of the curve representing cicatrization. J Exp Med. 1916;24: McGrath MH, Simon RH. Wound geometry and the kinetics of wound contraction. Plast Reconstr Surg. 1983;72: Kennedy DF, Cliff WJ. A systematic study of wound contraction in mammalian skin. Pathology. 1979;11: Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor-bb for the treatment of chronic pressure ulcers. Lancet. 1992; 339: Gilman TH. Parameter for measurement of wound closure. Wounds. 199;2: Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes. 1991;: Margolis DJ, Gross EA, Wood CR, Lazaus GS. Planimetric rate of healing in venous ulcers of the leg treated with pressure bandage and hydrocolloid dressing. J Am Acad Dermatol. 1993;28: Tallman P, Muscare E, Carson P, Eaglstein WH, Falanga V. Initial rate of healing predicts complete healing of venous ulcers. Arch Dermatol. 1997;133: Snowden JM. Wound closure: an analysis of the relative contributions of contraction and epithelialization. J Surg Res. 1984;37: Robson MC, Maggi SP, Smith PD, et al. Ease of wound closure as an endpoint of treatment efficacy. Wound Repair Regen. 1999;7: Lazurus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wound and evaluation of healing. Arch Dermatol. 1994;1: Stromberg K, Chapekar MS, Goldman BA, Chambers WA, Cavagnaro JA. Regulatory concerns in the development of topical recombinant ophthalmic and cutaneous wound healing biologies. Wound Repair Regen. 1994;2: Windsor CP. The Gompertz curve as a growth curve. Proc Natl Acad Sci. 1932; 18: Robson MC, Kucukcelebi A, Carp SS, et al. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis. 1994;13(suppl 2): Kucukcelebi A, Harries RHC, Hennessey PJ, et al. In vivo characterization of interleukin-4 as a potential wound healing agent. Wound Repair Regen. 1995;3: Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53: Polansky M, van Rijswijk L. Utilizing survival analysis techniques in chronic wound healing studies. Wounds. 1994;6: Peto R, Pike C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35: Wright T, Hill D, Polo M, et al. The modulation of acute incisional wound healing with r-tgfb2 and fibrin sealant [abstract]. Wound Repair Regen. 1997;5:A128. (REPRINTED) ARCH SURG/ VOL 135, JULY 777 Downloaded From: on 12/4/17 American Medical Association. All rights reserved.
The influence of wound geometry on the measurement of wound healing rates in clinical trials
The influence of wound geometry on the measurement of wound healing rates in clinical trials Daniel R. Gorin, MD, Paul R. Cordts, MD, Wayne W. LaMorte, MD, PhD, MPH, and James O. Menzoian, MD, Boston,
More informationA comprehensive study on effect of recombinant human epidermal growth factor gel in diabetic foot ulcer
Original Research Article A comprehensive study on effect of recombinant human epidermal growth factor gel in diabetic foot ulcer S Vijayalakshmi * Associate Professor, Department of General Surgery, Govt.
More informationCytokine manipulation of the wound
Clin Plastic Surg 30 (2003) 57 65 Cytokine manipulation of the wound Martin C. Robson, MD* Department of Surgery, University of South Florida, Tampa, FL 33620, USA * 3619 S.E. Cambridge Drive, Stuart,
More information1/5. Introduction. Primary endpoint Time to reach readiness for closure by surgical intervention or left for closure by secondary intention
1/5 Introduction Materials and methods Animal studies show that intermittent NPWT has potential to increase the rate of granulation tissue formation compared with adjustable intermittent (AI) NPWT 1 However,
More informationA comprehensive study on effect of collagen dressing in diabetic foot ulcer
Original Research Article A comprehensive study on effect of collagen dressing in diabetic foot ulcer Sivakumar 1, S. Shanmugam 2* 1 Associate Professor, 2 Senior Assistant Professor Department of General
More informationPrediction of healing for post-operative diabetic foot wounds based on early wound area progression
Diabetes Care Publish Ahead of Print, published online October 12, 2007 Prediction of healing for post-operative diabetic foot wounds based on early wound area progression Lawrence A Lavery, DPM, MPH 1
More informationSurrogate endpoints have been de ned by Prentice (1989)
ORIGINAL ARTICLE Surrogate Endpoints for the Treatment of Venous Leg Ulcers Joel M. Gelfand, n w Ole Ho stad,w and David J. Margolis n w n Department of Dermatology and the wcenter for Clinical Epidemiology
More information*Ramakrishna Y. Srinivas Institute of Medical Sciences and Research Centre, Mukka, Mangalore, Karnataka *Author for Correspondence
DRESSING WITH TOPICAL APPLICATION OF RECOMBINANT HUMAN PLATELET DERIVED GROWTH FACTOR GEL IN THE MANAGEMENT OF ACUTE AND CHRONIC WOUNDS: A PROSPECTIVE STUDY *Ramakrishna Y. Srinivas Institute of Medical
More informationClinical Review Criteria
Clinical Review Criteria Autologous Platelet Derived Wound Healing Factors for Treatment of: Non Healing Cutaneous Wounds (Procuren) Non-Healing Fractures and the Associated GEM 21STM Device Platelet Rich
More informationOriginal articles Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study
Original articles Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study RILEY S. REES, MD a ; MARTIN C. ROBSON, MD b ; JANICE M. SMIELL, MD
More informationSTUDY. complication of diabetes, affecting 12% to 15% of patients. during their lifetime. 1,2 Diabetic foot ulcers (DFUs) impair quality
STUDY Advanced Biological Therapies for Diabetic Foot Ulcers Robert S. Kirsner, MD, PhD; Robert Warriner, MD; Michelle Michela, MS; Laure Stasik, BA; Katherine Freeman, PhD Objective: To assess the clinical
More informationPrepares wounds to allow natural healing
ADVANCED CARE OF ACUTE AND CHRONIC WOUNDS Prepares wounds to allow natural healing 0373 Medical Device Hyaluronic Acid and Collagenase COMBINED ACTION IN WOUND REPAIR Hyaluronic acid and collagenase promote
More informationWOUND CARE UPDATE. -Commonly Used Skin Substitute Products For Wound. -Total Contact Casting. Jack W. Hutter DPM, FACFAS, C. ped.
WOUND CARE UPDATE -Commonly Used Skin Substitute Products For Wound Closure -Total Contact Casting Jack W. Hutter DPM, FACFAS, C. ped. Commonly Used Skin Substitute Products for Wound Closure why are they
More informationUnderstanding and Managing
Understanding and Managing MM s in Wound Bed Brock Liden DM, ABM, FAWCA Learning Objectives Review the four sequential phases of normal wound healing and recognize the BENEFICIAL effects of CONTROLLED
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationMean percent reduction in ulcer area from baseline at six weeks 62 % SANTYL Ointment + supportive care* + sharp debridement 1 (P<0.
Evaluating two common adjuncts to sharp debridement in the treatment of diabetic foot ulcers Mean percent reduction in ulcer area from baseline at six weeks 62 % 40 % SANTYL Ointment + supportive care*
More informationHemostasis Inflammatory Phase Proliferative/rebuilding Phase Maturation Phase
The presenters are staff members of the CHI Health St. Elizabeth Burn and Wound Center. Many of the products discussed are used in our current practice but we have no conflict of interest to disclose.
More informationThe Georgetown Team Approach to Diabetic Limb Salvage: 2013
The Georgetown Team Approach to Diabetic Limb Salvage: 2013 John S. Steinberg, DPM FACFAS Associate Professor, Department of Plastic Surgery Georgetown University School of Medicine Disclosures: None Need
More informationALLIANCE OF WOUND CARE STAKEHOLDERS. Palmetto GBA Public Meeting Draft LCD on Application of Skin Substitutes (DL36466) October 13, 2015
ALLIANCE OF WOUND CARE STAKEHOLDERS Palmetto GBA Public Meeting Draft LCD on Application of Skin Substitutes (DL36466) October 13, 2015 1 ALLIANCE OF WOUND CARE Who is the Alliance? STAKEHOLDERS A non-profit
More informationClinical. Summaries. 3M Tegaderm Matrix Matrix Dressing. Delayed wound healing: A major clinical problem
3M Tegaderm Matrix Matrix Dressing Clinical Summaries Delayed wound healing: A major clinical problem Chronic wounds have been defined as those that fail to progress through a normal, orderly, and timely
More informationIncreased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers
Diabetes Care Publish Ahead of Print, published online October 3, 2008 MMP-9 Predicts Wound Healing Increased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers Yu Liu, MD 1,
More informationClinical Summary. Introduction. What are Scars? There are three main types of scars:
Introduction Clinical Summary Since the introduction of silicone in the early 1980s for the prevention and treatment of hypertrophic & keloid scars, it s therapeutic effects have been well documented in
More informationRegenerative Tissue Matrix in Treatment of Wounds
Regenerative Tissue Matrix in Treatment of Wounds Learning Objectives Differentiate between reparative and regenerative healing Review surgical techniques for applying a regenerative tissue scaffold to
More informationDiabetic Foot Ulcer Treatment and Prevention
Diabetic Foot Ulcer Treatment and Prevention Alexander Reyzelman DPM, FACFAS Associate Professor California School of Podiatric Medicine at Samuel Merritt University Diabetic Foot Ulcers One of the most
More informationTreatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J
Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis Kantor J, Margolis D J Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationThe Role of the Autologous Platelet-Derived Growth Factor in the Management of Decubitus Ulcer
The Role of the Autologous Platelet-Derived Growth Factor in the Management of Decubitus Ulcer B. Aminian MD, M. Shams MD, B. Karim-Aghaee MD, M. Soveyd MD, Gh. R. Omrani MD Department of Internal Medicine,
More informationA New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology
A New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology Farheen Walid, BA, Shrunjay R. Patel, BSc, Stephanie Wu, DPM, MS Center for Lower Extremity Ambulatory Research (CLEAR), Scholl College
More informationFrequency of Debridements and Time to Heal A Retrospective Cohort Study of Wounds
Research Original Investigation Frequency of Debridements and Time to Heal A Retrospective Cohort Study of 312 744 Wounds James R. Wilcox, RN; Marissa J. Carter, PhD, MA; Scott Covington, MD IMPORTANCE
More informationPRP Usage in Today's Implantology
Volume 1, December 2004 www.implant.co.il PRP Usage in Today's Implantology by Dr. R. Shapira Introduction: Treating patients suffering from hematological disorders or using anticoagulant medications always
More informationEmbrace the Call to Wound Prevention and Care
CONCLUSION Embrace the Call to Wound Prevention and Care A challenging career Be part of an interprofessional team Help patients, families, communities Commit to lifelong learning To cure occasionally,
More informationPhysiology and Advancements in Wound Healing
Thomas Jefferson University Jefferson Digital Commons Department of Otolaryngology - Head and Neck Surgery Faculty, Presentations and Grand Rounds Department of Otolaryngology - Head and Neck Surgery 3-26-2014
More informationAuthors' objectives To assess the value of treatments for foot ulcers in patients with Type 2 diabetes mellitus.
A systematic review of foot ulcer in patients with Type 2 diabetes mellitus - II: treatment Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A Authors' objectives To assess the value of treatments
More informationRole of Growth Factors in the Treatment of Diabetic Foot Ulceration
20 Role of Growth Factors in the Treatment of Diabetic Foot Ulceration David L. Steed, MD PRINCIPLES OF WOUND HEALING AND GROWTH FACTOR THERAPY Wound healing is the process of tissue repair and the tissue
More informationDisclosures. Outpatient NPWT Options Free up Hospital Beds, but Do They Work? Objectives. Clinically Effective: Does it Work?
4/16/16 Disclosures Consultant, Volcano Corporation Outpatient Options Free up Hospital Beds, but Do They Work? UCSF Vascular Symposium 16 Jonathan Labovitz, DPM Medical Director, Foot & Ankle Center Associate
More informationAccelerating Phase II-III Oncology Drug Development Through the Use of Adaptive Designs
Accelerating Phase II-III Oncology Drug Development Through the Use of Adaptive Designs - Jonathan R. Smith, Ph.D. June 15th, 2004, DIA Annual Meeting, Washington Outline of Presentation Oncology Background
More informationWound Healing Stages
Normal Skin Wound Healing Stages Stages overlap Chronic wounds are stalled in the inflammatory phase COLLAGEN MATURATION MATRIX METALLOPROTEINASES ENDOTHELIAL CELLS EPITHELIAL CELLS MATRIX PROTEINS FIBROBLASTS
More informationQuality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer
Original article Annals of Oncology 16: 1458 1462, 25 doi:1.193/annonc/mdi275 Published online 9 June 25 Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women
More informationSmart Solutions for Serious Wounds. An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers.
Smart Solutions for Serious Wounds An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers. A New Approach to Diabetic Foot Ulcer Care Supported by Over Two
More informationEVIDENCE-BASED DERMATOLOGY: ORIGINAL CONTRIBUTION
Risk Factors for Delayed Healing of Neuropathic Diabetic Foot Ulcers A Pooled Analysis EVIDENCE-BASED DERMATOLOGY: ORIGINAL CONTRIBUTION David J. Margolis, MD, MSCE; Jonathan Kantor, MA; Jill Santanna,
More informationClinical Summary. treatment and prevention of hypertrophic scars have been well documented in the literature.
Introduction: Introduction: Since the introduction of silicone in the early 1980s, its therapeutic effects on predominantly the i, ii treatment and prevention of hypertrophic scars have been well documented
More informationSupplementary Online Content
Supplementary Online Content Rollman BL, Herbeck Belnap B, Abebe KZ, et al. Effectiveness of online collaborative care for treating mood and anxiety disorders in primary care: a randomized clinical trial.
More informationDefining Outcomes for Clinical Wound Research in Older Adults February 21, 2014
Defining Outcomes for Clinical Wound Research in Older Adults February 21, 214 Harold Brem, MD Professor of Surgery Stony Brook University School of Medicine Chief, Division of Wound Healing and Regenerative
More informationCost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers Sibbald R G, Torrance G, Hux M, Attard C, Milkovich N
Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers Sibbald R G, Torrance G, Hux M, Attard C, Milkovich N Record Status This is a critical abstract of an economic evaluation
More informationThe Patient and Observer Scar Assessment Scale: A Reliable and Feasible Tool for Scar Evaluation
The Patient and Observer Scar Assessment Scale: A Reliable and Feasible Tool for Scar Evaluation Lieneke J. Draaijers, M.D., Fenike R. H. Tempelman, M.D., Yvonne A. M. Botman, M.D., Wim E. Tuinebreijer,
More informationA Keloid Edge Precut, Preradiotherapy Method in Large Keloid Skin Graft Treatment
A Keloid Edge Precut, Preradiotherapy Method in Large Keloid Skin Graft Treatment WENBO LI, MD, YOUBIN WANG, MD, XIAOJUN WANG, MD, AND ZHIFEI LIU, MD* BACKGROUND Keloids are scars that extend beyond the
More informationFluorescence Angiography in Limb Salvage
Fluorescence Angiography in Limb Salvage Ryan H. Fitzgerald, DPM, FACFAS Associate Professor of Surgery-University Of South Carolina School of Medicine, Greenville Etiology of Lower extremity wounds Neuropathy
More informationWound Management. E. Foy White-Chu, MD, CWSP
Wound Management E. Foy White-Chu, MD, CWSP E. Foy White-Chu, MD, CWSP Assistant Professor, OHSU Wound Medical Director, VAPORHCS List the Four Principles of Wound Bed Preparation Determine safe debridement
More informationScott E. Palmer, V.M.D. Diplomate, A.B.V.P., Eq. Practice New Jersey Equine Clinic
Scott E. Palmer, V.M.D. Diplomate, A.B.V.P., Eq. Practice New Jersey Equine Clinic spalmer@njequine.com Hemostasis Inflammation Proliferation Remodeling Inflammation Matrix production Angiogenesis Epithelialization
More informationInteresting Case Series. Skin Grafting in Pyoderma Gangrenosum
Interesting Case Series Skin Grafting in Pyoderma Gangrenosum Marco Romanelli, MD, PhD, Agata Janowska, MD, Teresa Oranges, MD, and Valentina Dini, MD, PhD Department of Dermatology, University of Pisa,
More informationHydroTherapy: A simple approach to Wound Management
Copyright Paul Hartmann Pty Ltd material may not be reproduced or used without written permission HydroTherapy: A simple approach to Wound Management HARTMANN Education Agenda Agenda Acute vs Chronic wounds:
More informationA study to test the validity of diabetic ulcer severity score (DUSS) at tertiary care hospital
International Surgery Journal Kumar VH et al. Int Surg J. 2017 Dec;4(12):4010-4014 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20175401
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationHealing of Chronic Venous Ulcers Is Not Enhanced by the Addition of Topical Repifermin (KGF-2) to Standardized Care
Healing of Chronic Venous Ulcers Is Not Enhanced by the Addition of Topical Repifermin (KGF-2) to Standardized Care Martin C. Robson, MD a,b Jason Hanfnt, DPM c Warren Garner, MD d Jeffrey Jenson, DPM
More informationTo test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
More informationEarly Learning vs Early Variability 1.5 r = p = Early Learning r = p = e 005. Early Learning 0.
The temporal structure of motor variability is dynamically regulated and predicts individual differences in motor learning ability Howard Wu *, Yohsuke Miyamoto *, Luis Nicolas Gonzales-Castro, Bence P.
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-11-1-629 TITLE: Stabilized hemoglobin wound healing development PRINCIPAL INVESTIGATOR: Ross Tye CONTRACTING ORGANIZATION: IKOR Inc., Aberdeen, South Dakota 5741-262 REPORT DATE:
More informationAdvanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review
Department of Veterans Affairs Health Services Research & Development Service Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review November 2012 Prepared
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in
More informationJournal of Biostatistics and Epidemiology
Journal of Biostatistics and Epidemiology Original Article Usage of statistical methods and study designs in publication of specialty of general medicine and its secular changes Swati Patel 1*, Vipin Naik
More information1.4 - Linear Regression and MS Excel
1.4 - Linear Regression and MS Excel Regression is an analytic technique for determining the relationship between a dependent variable and an independent variable. When the two variables have a linear
More information3M Tegaderm Matrix Matrix Dressing. Matrix. Your questions answered
3M Tegaderm Matrix Matrix Dressing Matrix Your questions answered 3M Tegaderm Matrix Matrix Dressing Frequently Asked Questions What is Tegaderm Matrix? Matrix is a wound dressing impregnated with polyhydrated
More informationFor more information about how to cite these materials visit
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationThe Preventive Effect of Recombinant Human Growth Factor (rhegf) on the Recurrence of Radiodermatitis
J. Radiat. Res. Regular Paper The Preventive Effect of Recombinant Human Growth Factor (rhegf) on the Recurrence of Radiodermatitis Seung-Hee RYU 1, Yeun Hwa KIM 2, Sang-wook LEE 1 and Joon Pio HONG 2
More informationJMSCR Vol 06 Issue 03 Page March 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i3.55 Thesis Paper A Prospective Comparative
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More information3M Tegaderm Matrix Matrix Dressing. Conquer Non-healing. Wounds
Conquer Non-healing Wounds Chronic wounds Chronic wounds have been defined as those that fail to progress through a normal, orderly and timely sequence of repair. Or, wounds that pass through the repair
More informationTumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016
1 Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016 Philippe RUSZNIEWSKI ENETS Centre of Excellence, Beaujon Hospital, Clichy, France
More informationSource of effectiveness data The effectiveness evidence was derived from a review of published studies.
Cost and cost effectiveness of venous and pressure ulcer protocols of care Kerstein M D, Gemmen E, van Rijswijk L, Lyder C H, Phillips T, Xakellis G, Golden K, Harrington C Record Status This is a critical
More informationPopulation Enrichment Designs Case Study of a Large Multinational Trial
Population Enrichment Designs Case Study of a Large Multinational Trial Harvard Schering-Plough Workshop Boston, 29 May 2009 Cyrus R. Mehta, Ph.D Cytel Corporation and Harvard School of Public Health email:
More informationCleft lip is the most common craniofacial
Ideas and Innovations Fat Grafting in Primary Cleft Lip Repair Elizabeth Gordon Zellner, M.D. Miles J. Pfaff, M.D. Derek M. Steinbacher, M.D., D.M.D. New Haven, Conn. Summary: The goal of primary cleft
More informationSupplemental Table 1 Molecular Profile of the SCLC Cell Line Panel
Supplemental Table 1 Molecular Profile of the SCLC Cell Line Panel p53 RB Myc Cell Line Mutation A Mutation A Amplification B COR-L103 C p.y234c p.d584e L-Myc NCI-H526 p.s33_splice None N-Myc NCI-H1048
More informationClinical Applications for Change-Point Analysis of Herpes Zoster Pain
510 Journal of Pain and Symptom Management Vol. 23 No. 6 June 2002 Original Article Clinical Applications for Change-Point Analysis of Herpes Zoster Pain Renee A. Desmond, PhD, Heidi L. Weiss, PhD, Ramin
More informationChronic wounds need an ideal microenvironment. NEXODYN TM can support the physiological healing process.
Chronic wounds need an ideal microenvironment. can support the physiological healing process. Wound microenvironment of chronic wounds represents a major therapeutic challenge¹ The most relevant factors
More informationUse of Non-Contact Low Frequency Ultrasound in Wound Care
Use of Non-Contact Low Frequency Ultrasound in Wound Care BLAIRE CHANDLER SEPTEMBER 29, 2015 VCU DPT CLASS OF 2016 Objectives Patient case overview Examine clinical evidence Review intervention of interest
More informationInteresting Case Series. Creating Accurate Flap Designs Using a Hydrocolloid Dressing as a Template
Interesting Case Series Creating Accurate Flap Designs Using a Hydrocolloid Dressing as a Template Amra Kuc, BS a, Jared Gopman, MD b, and Deniz Dayicioglu, MD c a Morsani College of Medicine, University
More informationAccepted Manuscript. Wound Management Strategies in Stevens-Johnson syndrome/toxic Epidermal Necrolysis: An unmet need
Accepted Manuscript Wound Management Strategies in Stevens-Johnson syndrome/toxic Epidermal Necrolysis: An unmet need Lee Haur Yueh, MBBS, MRCP, MMed, FAMS PII: S0190-9622(18)32138-8 DOI: 10.1016/j.jaad.2018.05.1258
More informationIPM Wound Gel Bio A New High Concentration (2.5%) Hyaluronic Acid (HA) Based Gel Treatment of Chronic Wounds
IPM Wound Gel Bio A New High Concentration (2.5%) Hyaluronic Acid (HA) Based Gel Treatment of Chronic Wounds Part 1 of 3 Chronic wounds: widely considered to be stuck in the inflammatory phase Hyaluronic
More informationTITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer
AD Award Number: W81XWH-04-1-0769 TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer PRINCIPAL INVESTIGATOR: Richard K. Valicenti,
More informationDressings do not heal wounds properly selected dressings enhance the body s ability to heal the wound. Progression Towards Healing
Dressings in Wound Care: They Do Matter John S. Steinberg, DPM FACFAS Associate Professor, Department of Plastic Surgery Georgetown University School of Medicine Dressings do not heal wounds properly selected
More informationInflammation is Not the Enemy
6/22/2017 Inflammation is Not the Enemy Sean Mulvaney, MD 1 6/22/2017 2 6/22/2017 Lascaux 7.4 Billion 3 This image cannot currently be displayed. 6/22/2017 Goals 4 ANTI INFLAMMATORY THERAPIES NSAIDS 5
More informationCURRICULUM VITAE GERARD C. MOSIELLO, MD, FACS
CURRICULUM VITAE GERARD C. MOSIELLO, MD, FACS Tampa Palms Plastic Surgery 15243 Amberly Dr. Tampa, FL 33647 (813) 503-6429 cell (813) 631-1500 office (813) 631-1600 fax jerry@tampapalmsplasticsurgery.com
More informationClinical Policy Title: Vacuum assisted closure in surgical wounds
Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Number: 17.03.00 Effective Date: September 1, 2015 Initial Review Date: June 16, 2013 Most Recent Review Date: August 17,
More informationStatistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche
Statistical Challenges in Immunotherapy: Non Proportional Hazard Model BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche 1 Statistical Challenges Biomarker Efficacy Endpoint Study Design & Analysis
More informationApplication of Cox Regression in Modeling Survival Rate of Drug Abuse
American Journal of Theoretical and Applied Statistics 2018; 7(1): 1-7 http://www.sciencepublishinggroup.com/j/ajtas doi: 10.11648/j.ajtas.20180701.11 ISSN: 2326-8999 (Print); ISSN: 2326-9006 (Online)
More informationSPSS Portfolio. Brittany Murray BUSA MWF 1:00pm-1:50pm
SPSS Portfolio Brittany Murray BUSA 2182 MWF 1:00pm-1:50pm Table Of Contents I) SPSS Computer Lab Assignment # 1 Frequency Distribution a) Cover Page b) Explanatory Paragraph c) Appendix II) SPSS Computer
More informationEmerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment
9 th Annual New Cardiovascular Horizons New Orleans September 12, 2008 Emerging Use of Topical Biologics in Limb Salvage Role of Activated Collagen in Multimodality Treatment Gary M. Rothenberg, DPM, CDE,
More informationEvaluation of Models to Estimate Urinary Nitrogen and Expected Milk Urea Nitrogen 1
J. Dairy Sci. 85:227 233 American Dairy Science Association, 2002. Evaluation of Models to Estimate Urinary Nitrogen and Expected Milk Urea Nitrogen 1 R. A. Kohn, K. F. Kalscheur, 2 and E. Russek-Cohen
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationPremier Health Plan considers Negative Pressure Wound Therapy (NPWT) in the home setting medically necessary for the following indications:
Premier Health Plan POLICY AND PROCEDURE MANUAL PA.009.PH Negative Pressure Wound Therapy This policy applies to the following lines of business: Premier Commercial Premier Employee Premier Health Plan
More informationClinical Study to Compare the Efficacy of Platelet Rich Plasma versus Conventional Dressing in Chronic Non-Healing Ulcers
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 3 Ver. 3 March. (2018), PP 42-46 www.iosrjournals.org Clinical Study to Compare the Efficacy
More informationWright Medical Technology, Inc Airline Road Arlington, TN phone toll-free
References 1 Brigido SA, Boc SF, Lopez RC. Effective Management of Major Lower Extremity Wounds Using an Acellular Regenerative Tissue Matrix: A Pilot Study. Orthopedics 2004; 27(1S): pp145-149. 2 Brigido
More informationA Comparison of Shape and Scale Estimators of the Two-Parameter Weibull Distribution
Journal of Modern Applied Statistical Methods Volume 13 Issue 1 Article 3 5-1-2014 A Comparison of Shape and Scale Estimators of the Two-Parameter Weibull Distribution Florence George Florida International
More informationUse of an Acellular Regenerative Tissue Matrix Over Chronic Wounds
Use of an Acellular Regenerative Tissue Matrix Over Chronic Wounds D. Heath Stacey, MD Northwest Arkansas Center for Plastic Surgery, Fayetteville, Ark Correspondence: dheathstacey@gmail.com Keywords:
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationTokyo, Japan; and c Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
CASE REPORT Easy-to-Use Preservation and Application of Platelet-Rich Plasma in Combination Wound Therapy With a Gelatin Sheet and Freeze-Dried Platelet-Rich Plasma: A Case Report Naoki Morimoto, MD, a
More informationAdjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU)
Adjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU) Sami Khan, MD FACS Associate Professor of Surgery Division of Plastic and Reconstructive Surgery SUNY-Stony
More informationThe Risk. Background / Bias. Integrating Wound Care into a Limb Preservation Initiative 4/24/2009
Stimulating Wound Granulation: Advances in NPWT and other Measures (Wound Bed Preparation) Charles Andersen MD, FACS, FAPWCA Clinical Prof of Surgery UW, USUHS Chief Vascular/Endovascular/ Limb Preservation
More information